Clinical profiles and prognosis of patients with distinct antisynthetase autoantibodies

Journal of Rheumatology

Volumn 44, Issue 7, 2017, Pages 1051-1057

  Shi, Jingli ^a   Li, Shanshan ^a   Yang, Hanbo ^a   Zhang, Yamei ^a   Peng, Qinglin ^a   Lu, Xin ^a   Wang, Guochun ^a  

^a CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Anti Ro52 antibody; Anti tRNA synthetase antibody; Prognostic factors; Rapidly progressive interstitial lung disease

Indexed keywords

AUTOANTIBODY; EJ ANTIBODY; FERRITIN; JO 1 ANTIBODY; PL12 ANTIBODY; PL7 ANTIBODY; RO52 ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ANTISYNTHETASE SYNDROME; ARTHRALGIA; ARTICLE; BRONCHOALVEOLAR LAVAGE FLUID; CHINESE; CLINICAL FEATURE; COHORT ANALYSIS; COMPUTER ASSISTED TOMOGRAPHY; DISEASE COURSE; DYSPHAGIA; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; INTERSTITIAL LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; MYALGIA; NEUTROPHIL COUNT; PAPULE; PERICARDITIS; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RASH; RETROSPECTIVE STUDY; SURVIVAL RATE; BLOOD; DIAGNOSTIC IMAGING; IMMUNOLOGY; MIDDLE AGED; MYOSITIS; PREVALENCE; SYMPTOM ASSESSMENT; X-RAY COMPUTED TOMOGRAPHY;

ADULT; AGED; AUTOANTIBODIES; FEMALE; HUMANS; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; MYOSITIS; PREVALENCE; PROGNOSIS; RETROSPECTIVE STUDIES; SYMPTOM ASSESSMENT; TOMOGRAPHY, X-RAY COMPUTED;

EID: 85021806978     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.161480     Document Type: Article

References (40)

1. Mammen AL. Dermatomyositis and polymyositis: clinical presentation, autoantibodies, and pathogenesis. Ann N Y Acad Sci 2010;1184:134-53.
2. Mimori T, Imura Y, Nakashima R, Yoshifuji H. Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 2007;19:523-9.
3. Casciola-Rosen L, Mammen AL. Myositis autoantibodies. Curr Opin Rheumatol 2012;24:602-8.
4. Sordet C, Goetz J, Sibilia J. Contribution of autoantibodies to the diagnosis and nosology of inflammatory muscle disease. Joint Bone Spine 2006;73:646-54.
5. Hamaguchi Y, Fujimoto M, Matsushita T, Kaji K, Komura K, Hasegawa M, et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: heterogeneity within the syndrome. PLoS One 2013;8:e60442.
6. Dugar M, Cox S, Limaye V, Blumbergs P, Roberts-Thomson PJ. Clinical heterogeneity and prognostic features of South Australian patients with anti-synthetase autoantibodies. Intern Med J 2011;41:674-9.
7. Hervier B, Benveniste O. Clinical heterogeneity and outcomes of antisynthetase syndrome. Curr Rheumatol Rep 2013;15:349.
8. Yamasaki Y, Satoh M, Mizushima M, Okazaki T, Nagafuchi H, Ooka S, et al. Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52. Mod Rheumatol 2016;26:403-9.
9. Kryštufková O, Barbasso Helmers S, Venalis P, Malmström V, Lindroos E, Vencovský J, et al. Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies. Arthritis Res Ther 2014;16:454.
10. Ghillani P, Andre C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev 2011;10:509-13.
11. La Corte R, Lo Mo Naco A, Locaputo A, Dolzani F, Trotta F. In patients with antisynthetase syndrome the occurrence of anti-Ro/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 2006;39:249-53.
12. Váncsa A, Csípo I, Németh J, Dévényi K, Gergely L, Dankó K. Characteristics of interstitial lung disease in SS-A positive/Jo-1 positive inflammatory myopathy patients. Rheumatol Int 2009;29:989-94.
13. Bauhammer J, Blank N, Max R, Lorenz HM, Wagner U, Krause D, et al. Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response. J Rheumatol 2016;43:1566-74.
14. Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 2012;41:890-9.
15. Tieu J, Lundberg IE, Limaye V. Idiopathic inflammatory myositis. Best Pract Res Clin Rheumatol 2016;30:149-68.
16. Solomon J, Swigris JJ, Brown KK. Myositis-related interstitial lung disease and antisynthetase syndrome. J Bras Pneumol 2011; 37:100-9.
17. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-64.
18. Gono T, Kawaguchi Y, Satoh T, Kuwana M, Katsumata Y, Takagi K, et al. Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology 2010;49:1713-9.
19. Trallero-Araguás E, Grau-Junyent JM, Labirua-Iturburu A, García-Hernández FJ, Monteagudo-Jiménez M, Fraile-Rodriguez G, et al. Clinical manifestations and long-term outcome of anti-Jo1 antisynthetase patients in a large cohort of Spanish patients from the GEAS-IIM group. Semin Arthritis Rheum 2016;46:225-31.
20. Kalluri M, Sahn SA, Oddis CV, Gharib SL, Christopher-Stine L, Danoff SK, et al. Clinical profile of anti-PL-12 autoantibody. Cohort study and review of the literature. Chest 2009;135:1550-6.
21. Johnson C, Connors GR, Oaks J, Han S, Truong A, Richardson B, et al. Clinical and pathologic differences in interstitial lung disease based on antisynthetase antibody type. Respir Med 2014;108:1542-8.
22. Andersson H, Aaløkken TM, Günther A, Mynarek GK, Garen T, Lund MB, et al. Pulmonary involvement in the antisynthetase syndrome: A comparative cross-sectional study. J Rheumatol 2016;43:1107-13.
23. Kim SH, Park IN. Acute respiratory distress syndrome as the initial clinical manifestation of an antisynthetase syndrome. Tuberc Respir Dis 2016;79:188-92.
24. Bajocchi G, Piro R, Lombardini C, Cavazza A, Facciolongo N. Acute respiratory distress syndrome: an undercover antisynthetase syndrome: A case report and a review of the literature. Clin Exp Rheumatol 2012;30:424-8.
25. Polosa R, Di Mauro C, Spampinato B, Castelli L, D'Amico G, Edwards CJ, et al. A patient with antihistidyl-tRNA synthetase positive polymyositis presenting as acute respiratory distress syndrome. J Clin Rheumatol 2008;14:219-21.
26. Piroddi IM, Ferraioli G, Barlascini C, Castagneto C, Nicolini A. Severe respiratory failure as a presenting feature of an interstitial lung disease associated with anti-synthetase syndrome (ASS). Respir Investig 2016;54:284-8.
27. Marie I, Josse S, Decaux O, Dominique S, Diot E, Landron C, et al. Comparison of long-term outcome between anti-Jo1-and anti-PL7/PL12 positive patients with antisynthetase syndrome. Autoimmun Rev 2012;11:739-45.
28. Hervier B, Devilliers H, Stanciu R, Meyer A, Uzunhan Y, Masseau A, et al. Hierarchical cluster and survival analyses of antisynthetase syndrome: phenotype and outcome are correlated with anti-tRNA synthetase antibody specificity. Autoimmun Rev 2012;12:210-7.
29. Hervier B, Uzunhan Y, Hachulla E, Benveniste O, Nunes H, Delaval P, et al. Antisynthetase syndrome positive for anti-threonyl-tRNA synthetase (anti-PL7) antibodies. Eur Respir J 2011;37:714-7.
30. Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, Danko K, Vencovsky J, Fisher B, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine 2012;91:206-11.
31. Keir GJ, Maher TM, Hansell DM, Denton CP, Ong VH, Singh S, et al. Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. Eur Respir J 2012;40:641-8.
32. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum 2005;52:2439-46.
33. Kotani T, Takeuchi T, Makino S, Hata K, Yoshida S, Nagai K, et al. Combination with corticosteroids and cyclosporin-A improves pulmonary function test results and chest HRCT findings in dermatomyositis patients with acute/subacute interstitial pneumonia. Clin Rheumatol 2011;30:1021-8.
34. Tillie-Leblond I, Wislez M, Valeyre D, Crestani B, Rabbat A, Israel-Biet D, et al. Interstitial lung disease and anti-Jo-1 antibodies: difference between acute and gradual onset. Thorax 2008;63:53-9.
35. Stanciu R, Guiguet M, Musset L, Touitou D, Beigelman C, Rigolet A, et al. Antisynthetase syndrome with anti-Jo1 antibodies in 48 patients: pulmonary involvement predicts disease-modifying antirheumatic drug use. J Rheumatol 2012;39:1835-9.
36. Hozumi H, Enomoto N, Kono M, Fujisawa T, Inui N, Nakamura Y, et al. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis/dermatomyositis-associated interstitial lung disease: A retrospective case control study. PLoS One 2015;10:e0120313.
37. Yousem SA, Schneider F, Bi D, Oddis CV, Gibson K, Aggarwal R. The pulmonary histopathologic manifestations of the anti-PL7/antithreonyl transfer RNA synthetase syndrome. Hum Pathol 2014;45:1199-204.
38. Gono T, Kawaguchi Y, Hara M, Masuda I, Katsumata Y, Shinozaki M, et al. Increased ferritin predicts development and severity of acute interstitial lung disease as a complication of dermatomyositis. Rheumatology 2010;49:1354-60.
39. Xu Y, Yang CS, Li YJ, Liu XD, Wang JN, Zhao Q, et al. Predictive factors of rapidly progressive-interstitial lung disease in patients with clinically amyopathic dermatomyositis. Clin Rheumatol 2016;35:113-6.
40. Chinoy H, Fertig N, Oddis CV, Ollier WE, Cooper RG. The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis. Ann Rheum Dis 2007;66:1345-9.